Results 1 to 10 of about 15,361 (206)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer [PDF]
New England Journal of Medicine, 2011 Data are lacking on the efficacy and safety of a combination chemotherapy regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) as compared with gemcitabine as first-line therapy in patients with metastatic pancreatic cancer.We randomly assigned 342 patients with an Eastern Cooperative Oncology Group performance ...
Thierry Conroy +2 more
exaly +8 more sources
Multi-Institutional experience with FOLFIRINOX in pancreatic adenocarcinoma [PDF]
JOP : Journal of the pancreas, 2012 Combination chemotherapy with FOLFIRINOX (oxaliplatin, irinotecan, fluorouracil, and leucovorin) was shown to be effective in a large phase III trial.
Gao, Feng +12 more
core +6 more sources
A phase 2 study of orally administered live biotherapeutic salmonella-IL2 with FOLFIRINOX for stage IV pancreatic cancer [PDF]
Cancer Immunology, ImmunotherapySalmonella-IL2 is an attenuated Salmonella Typhimurium strain carrying the human gene for IL-2. When orally administered in preclinical trials, the bacterium colonizes tumors and locally releases IL-2, triggering immunologically-mediated tumor cell ...
Gerald Batist +6 more
doaj +2 more sources
Treatment of initially unresectable local advanced pancreatic adenocarcinoma with FOLFIRINOX: A prospective study YCOG1403 (C-FLAP study) [PDF]
Scientific ReportsThis study aimed to provide evidence regarding the treatment of patients with unresectable pancreatic cancer. We conducted a prospective single-arm phase II trial using the FOLFIRINOX regimen.
Noritoshi Kobayashi +13 more
doaj +2 more sources
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
New England Journal of Medicine, 2018 Among patients with metastatic pancreatic cancer, combination chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) leads to longer overall survival than gemcitabine therapy. We compared the efficacy and safety of a modified FOLFIRINOX regimen with gemcitabine as adjuvant therapy in patients with resected pancreatic ...
Thierry Conroy +2 more
exaly +4 more sources
Cancer Communications, 2018 Background Combination therapy with oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) chemotherapy drastically improves survival of advanced pancreatic cancer patients. However, the efficacy of FOLFIRINOX as a second-line treatment after
Young Hwa Kim +2 more
exaly +3 more sources
Second-line Modified GTX versus Gemcitabine-Nab-Paclitaxel (GmAb) Following First-Line FOLFIRINOX in Advanced Pancreatic Cancer: A Retrospective Analysis at the American University of Beirut Medical Center (AUBMC) [PDF]
Middle East Journal of Cancer, 2023 Background: Pancreatic cancer is characterized by its generally poor prognosis and ranks seventh worldwide in cancer-related mortality. We previously conducted a prospective study on the use of modified GTX regimen (a combination of gemcitabine ...
Sally Temraz +5 more
doaj +1 more source
Gut and Liver, 2021 Background/Aims: Although many studies have reported the promising effect of neoadjuvant treatment for borderline resectable pancreatic cancer (BRPC) to increase resectability, only a few studies have recommended the use of first-line chemotherapeutic ...
Yoo Jin Choi +15 more
doaj +1 more source
Case Reports in Oncology, 2020 Pancreatic ductal adenocarcinoma (PDAC) is typically diagnosed at an advanced or metastatic stage, when curative surgery is not recommended. Therefore, the prognosis is poor for this dismal disease, with only 1–2% of the patients reaching the 5-year ...
Dilara Akhoundova Sanoyan +3 more
doaj +1 more source